This study was initiated due to an NIH “Facilities of Research—Spinal Cord Injury” contract
to support independent replication of published studies that could be considered for a …

Preclinical studies have attributed neuroprotective properties to the antibiotic minocycline.
Animal studies and early clinical trials support its use in several neurological diseases. In …

Acute spinal cord injury (SCI) produces tissue damage that continues to evolve days and
weeks after the initial insult, with corresponding functional impairments. Reducing the extent …

We examined the effects of minocycline, an anti-inflammatory drug, on functional recovery
following spinal cord injury (SCI). Rats received a mild, weight-drop contusion injury to the …

Minocycline (MC), a second-generation tetracycline and anti-inflammatory agent reportedly
provides neuroprotection following CNS injury. The objective of this study was to examine …

Study design. A prospective, randomized experimental research. Objective. To evaluate the
short-and long-term neuroprotective effects of minocycline on the secondary injury process …

Study Design. A prospective, randomized laboratory investigation. Objective. To investigate
whether administration of minocycline attenuates hind-limb motor dysfunction and gray and …

Minocycline is currently under development as a neuroprotective agent in many different
brain diseases. In more than a dozen experimental investigations in various models of brain …

Acute brain injury is a leading cause of morbidity and mortality worldwide. The term is
inclusive of traumatic brain injury, cerebral ischemia, subarachnoid hemorrhage, and …

Background: Minocycline is a pleomorphic neuroprotective agent well studied in animal
models of traumatic brain injury (TBI) and brain ischemia. Methods: To test the hypothesis …